Global Strategy for the Diagnosis, Management and Prevention of COPD [Internet]. Global Initiative for Chronic Obstructive Lung Disease -GOLD. [cité 2 juin 2017]. Disponible sur: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd, 2017. ,
Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease, American Journal of Respiratory and Critical Care Medicine, vol.11, issue.2, pp.155-61, 2012. ,
DOI : 10.1016/j.pcrj.2005.09.001
Cardiovascular Risk, Myocardial Injury, and Exacerbations of Chronic Obstructive Pulmonary Disease, American Journal of Respiratory and Critical Care Medicine, vol.185, issue.9, pp.1091-1100, 2013. ,
DOI : 10.1161/CIRCULATIONAHA.105.601641
Complex chronic comorbidities of COPD, European Respiratory Journal, vol.31, issue.1, pp.204-216, 2008. ,
DOI : 10.1183/09031936.00114307
URL : http://erj.ersjournals.com/content/erj/31/1/204.full.pdf
Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype, PLoS ONE, vol.80, issue.5, p.37483, 2012. ,
DOI : 10.1371/journal.pone.0037483.s009
Management of chronic obstructive pulmonary disease beyond the lungs, The Lancet Respiratory Medicine, vol.4, issue.11, pp.911-935, 2016. ,
DOI : 10.1016/S2213-2600(16)00097-7
Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis, The Lancet Respiratory Medicine, vol.3, issue.8, pp.631-640, 2015. ,
DOI : 10.1016/S2213-2600(15)00241-6
Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality Disponible sur: https, PLoS ONE, vol.12, issue.4, p.2017, 2017. ,
Non-alcoholic fatty liver disease: A sign of systemic disease, Metabolism, vol.72, pp.94-108, 2017. ,
DOI : 10.1016/j.metabol.2017.04.011
Recommandations de Pratique Clinique de EASL?EASD-EASO sur la prise en charge de la stéatopathie métabolique, J Hepatol, vol.64, pp.1388-1402, 2016. ,
The Natural Course of Non-Alcoholic Fatty Liver Disease Disponible sur: https, Int J Mol Sci, vol.17, issue.5, 2016. ,
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study, Gastroenterology, vol.129, issue.1, pp.113-134, 2005. ,
DOI : 10.1053/j.gastro.2005.04.014
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, vol.24, issue.1, pp.73-84, 2016. ,
DOI : 10.1111/j.1440-1746.2009.05831.x
URL : http://onlinelibrary.wiley.com/doi/10.1002/hep.28431/pdf
Hepatic steatosis: A benign disease or a silent killer, World Journal of Gastroenterology, vol.14, issue.26, pp.4120-4126, 2008. ,
DOI : 10.3748/wjg.14.4120
URL : http://europepmc.org/articles/pmc2725370?pdf=render
Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States, Gastroenterology, vol.141, issue.4, pp.1249-53, 2011. ,
DOI : 10.1053/j.gastro.2011.06.061
NAFLD: A multisystem disease, Journal of Hepatology, vol.62, issue.1, pp.47-64, 2015. ,
DOI : 10.1016/j.jhep.2014.12.012
URL : https://doi.org/10.1016/j.jhep.2014.12.012
Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?, European Heart Journal, vol.283, issue.10, pp.1190-200, 2012. ,
DOI : 10.1001/jama.283.15.2008
Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications, Journal of Hepatology, vol.65, issue.2, pp.425-443, 2016. ,
DOI : 10.1016/j.jhep.2016.04.005
Non-alcoholic fatty liver disease and risk of cardiovascular disease, Metabolism, vol.65, issue.8, pp.1136-50, 2016. ,
DOI : 10.1016/j.metabol.2015.09.017
The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis, Clinics in Liver Disease, vol.20, issue.2, pp.225-268, 2016. ,
DOI : 10.1016/j.cld.2015.10.002
Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome, Visceral Medicine, vol.32, issue.5, pp.329-363, 2016. ,
DOI : 10.1159/000448940
Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups, Digestive and Liver Disease, vol.47, issue.12, pp.997-1006, 2015. ,
DOI : 10.1016/j.dld.2015.08.004
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, Diseases, and American College of Gastroenterology, pp.1592-609, 2012. ,
DOI : 10.1053/j.gastro.2012.04.001
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis, Thorax, vol.59, issue.7, pp.574-80, 2004. ,
DOI : 10.1136/thx.2003.019588
Multiple Circulating Cytokines Are Coelevated in Chronic Obstructive Pulmonary Disease, Mediators of Inflammation, vol.13, issue.11, p.3604842, 2016. ,
DOI : 10.1371/journal.pone.0006053
URL : http://doi.org/10.1155/2016/3604842
High Prevalence of Obstructive Sleep Apnea in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease, Ann Am Thorac Soc. août, vol.12, issue.8, pp.1219-1244, 2015. ,
Predictors of the Overlap Syndrome and Its Association with Comorbidities in Patients with Chronic Obstructive Pulmonary Disease, Respiration, vol.88, issue.6, pp.451-458, 2014. ,
DOI : 10.1159/000368615
Nonalcoholic fatty liver disease and obstructive sleep apnea, Metabolism, vol.65, issue.8, pp.1124-1159, 2016. ,
DOI : 10.1016/j.metabol.2016.05.004
URL : https://hal.archives-ouvertes.fr/hal-01346101
Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese, Journal of Hepatology, vol.56, issue.1, pp.225-258, 2012. ,
DOI : 10.1016/j.jhep.2011.04.022
Nonalcoholic Fatty Liver Disease, Nocturnal Hypoxia, and Endothelial Function in Patients With Sleep Apnea, Chest, vol.145, issue.3, pp.525-558, 2014. ,
DOI : 10.1378/chest.13-0938
Metabolic Syndrome and the Lung, Chest, vol.149, issue.6, pp.1525-1559, 2016. ,
DOI : 10.1016/j.chest.2015.12.034
Central Fat and Peripheral Muscle, American Journal of Respiratory and Critical Care Medicine, vol.34, issue.1, pp.8-13, 2013. ,
DOI : 10.1016/j.cell.2012.01.017
Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study, European Respiratory Journal, vol.35, issue.2, pp.317-340, 2010. ,
DOI : 10.1183/09031936.00024709
URL : http://erj.ersjournals.com/content/erj/35/2/317.full.pdf
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease, European Respiratory Journal, vol.49, issue.6, p.1601923, 2017. ,
DOI : 10.1183/13993003.01923-2016.Supp1
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience, J Gastrointestin Liver Dis, vol.17, issue.2, pp.187-91, 2008. ,
FibroMAX???: towards a new universal biomarker of liver disease?, Expert Review of Molecular Diagnostics, vol.22, issue.5, pp.481-90, 2007. ,
DOI : 10.1016/0168-8278(95)80226-6
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease, BMC Gastroenterology, vol.277, issue.1, p.6, 2006. ,
DOI : 10.1074/jbc.M107771200
Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, vol.38, issue.6, pp.1313-1334, 2005. ,
DOI : 10.1002/hep.20701
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis, Comparative Hepatology, vol.4, issue.1, p.10, 2005. ,
DOI : 10.1186/1476-5926-4-10
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nature Reviews Gastroenterology & Hepatology, vol.31, issue.6, pp.330-374, 2013. ,
DOI : 10.1055/s-0031-1276643
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease, New England Journal of Medicine, vol.363, issue.14, pp.1341-50, 2010. ,
DOI : 10.1056/NEJMra0912063
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis, Journal of Hepatology, vol.65, issue.3, pp.589-600, 2016. ,
DOI : 10.1016/j.jhep.2016.05.013
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.149, issue.2, pp.389-397, 2015. ,
DOI : 10.1053/j.gastro.2015.04.043
URL : http://europepmc.org/articles/pmc4516664?pdf=render
, Cardiovascular Comorbidity in COPD: Systematic Literature Review. Chest. 1 oct, vol.144, issue.4, pp.1163-78, 2013.
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease, Thorax, vol.57, issue.10, pp.847-52, 2002. ,
DOI : 10.1136/thorax.57.10.847
Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care, Thorax, vol.65, issue.11, pp.956-62, 2010. ,
DOI : 10.1136/thx.2009.128082
Abdominal Visceral Adipose Tissue is Associated with Myocardial Infarction in Patients with COPD, Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, vol.2, issue.1, pp.8-16 ,
DOI : 10.15326/jcopdf.2.1.2015.0127
Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes, Thorax, vol.66, issue.5, pp.430-437, 2011. ,
DOI : 10.1136/thx.2010.154484
The recent advances of phenotypes in acute exacerbations of COPD, International Journal of Chronic Obstructive Pulmonary Disease, vol.12, 2017. ,
DOI : 10.2147/COPD.S128604
Clinical Characterization and Treatment Patterns for the Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease with Severe or Very Severe Airflow Limitation, COPD: Journal of Chronic Obstructive Pulmonary Disease, vol.42, issue.57, pp.15-22, 2017. ,
DOI : 10.4104/pcrj.2013.00016
The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review, COPD: Journal of Chronic Obstructive Pulmonary Disease, vol.3, issue.1, pp.399-406, 2016. ,
DOI : 10.2337/diacare.28.9.2289
Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study Disponible sur: https, Eur Respir J [Internet], vol.49, issue.5 ,
, COPD comorbidities network Eur Respir J. sept, vol.46, issue.3, pp.640-50, 2015.
Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada, Annals of Epidemiology, vol.16, issue.1, pp.63-70, 2006. ,
DOI : 10.1016/j.annepidem.2005.04.008
Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD, Thorax, vol.32, issue.(Suppl 6), pp.133-173, 2016. ,
DOI : 10.1183/09031936.00129507
The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease, Thorax, vol.67, issue.11, pp.970-976, 2012. ,
DOI : 10.1136/thoraxjnl-2012-202103
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement, Metabolism, vol.71, pp.17-32, 2017. ,
DOI : 10.1016/j.metabol.2017.02.014
Treatment of Non-Alcoholic Fatty Liver Disease, Digestive Diseases, vol.34, issue.1, pp.27-31, 2016. ,
DOI : 10.1159/000447278